Cubist Pharmaceuticals Given Consensus Rating of “Buy” by Brokerages (NASDAQ:CBST)
Cubist Pharmaceuticals (NASDAQ:CBST) has been given a consensus rating of “Buy” by the fifteen ratings firms that are covering the company, AnalystRatings.Net reports. Five research analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $79.08.
A number of analysts have recently weighed in on CBST shares. Analysts at JMP Securities downgraded shares of Cubist Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, July 23rd. They now have a $80.00 price target on the stock. Separately, analysts at Aegis reiterated a “positive” rating on shares of Cubist Pharmaceuticals in a research note on Monday, June 23rd. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Cubist Pharmaceuticals in a research note on Monday, June 23rd. They now have a $88.00 price target on the stock, up previously from $87.00.
Cubist Pharmaceuticals (NASDAQ:CBST) traded up 0.69% on Wednesday, hitting $61.975. 66,504 shares of the company’s stock traded hands. Cubist Pharmaceuticals has a one year low of $58.50 and a one year high of $82.12. The stock has a 50-day moving average of $67.63 and a 200-day moving average of $70.60. The company has a market cap of $4.683 billion and a P/E ratio of 539.91.
Cubist Pharmaceuticals (NASDAQ:CBST) last posted its quarterly earnings results on Tuesday, July 22nd. The company reported $0.23 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.01 by $0.22. The company had revenue of $294.40 million for the quarter, compared to the consensus estimate of $299.60 million. During the same quarter last year, the company posted $0.42 earnings per share. Cubist Pharmaceuticals’s revenue was up 13.8% compared to the same quarter last year. Analysts expect that Cubist Pharmaceuticals will post $0.71 EPS for the current fiscal year.
In other Cubist Pharmaceuticals news, EVP Steven C. Gilman unloaded 40,625 shares of Cubist Pharmaceuticals stock on the open market in a transaction dated Monday, July 28th. The shares were sold at an average price of $61.57, for a total transaction of $2,501,281.25. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.